Approved Technologies

The SAFETY Act provides two levels of liability protections for approval: Designation and Certification. By obtaining either Designation or Certification, companies obtain a level of legal protection in case their technology is ever put to use during a terrorist attack. See below for a list of approved technology certifications.

Company/Technology
BioPort Corporation Approved: June 27, 2022 | Expires: June 30, 2027 Emergent BioDefense Operations Lansing LLC provides BioThrax® (the "Technology"). The Technology is a sterile liquid suspension made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. The Technology is U.S. Food and Drug Administration ("FDA")-licensed for active immunization of individuals between 18 and 65 years of age to prevent disease caused by Bacillus anthracis. The Technology is to be administered and used in a manner consistent with its FDA licensing as a pre-exposure prophylaxis or as directed by the U.S. Government as a post-exposure prophylaxis. The Technology also includes manufacturing, testing, labeling, packaging, and storage of BioThrax®, as well as the associated technical documents and manuals
Emergent BioDefense Operations Lansing LLC Approved: August 26, 2016 | Expires: September 30, 2021 Emergent BioDefense Operations Lansing LLC provides BioThrax® (the “Technology”). The Technology is a sterile liquid suspension made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. The Technology is U.S. Food and Drug Administration (“FDA”)-licensed for active immunization of individuals between 18 and 65 years of age to prevent disease caused by Bacillus anthracis. The Technology is to be administered and used in a manner consistent with its FDA licensing as a pre-exposure prophylaxis or as directed by the U.S. Government as a post-exposure prophylaxis. The Technology also includes manufacturing, testing, labeling, packaging, and storage of BioThrax®, as well as the associated technical documents and manuals.
Emergent BioDefense Operations Lansing LLC Approved: August 09, 2011 | Expires: September 20, 2016 Emergent BioDefense Operations Lansing LLC provides BioThrax®. The Technology is a sterile liquid suspension made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. The Technology is U.S. Food and Drug Administration (FDA)-licensed for active immunization of individuals between 18 and 65 years of age to prevent disease caused by B. anthracis. The Technology is to be administered and used in a manner consistent with its FDA licensing as a pre-exposure prophylaxis or as directed by the U.S. Government as a post-exposure prophylaxis. The Technology also includes manufacturing, testing, labeling, packaging, and storage of BioThrax®, as well as the associated technical documents and manuals.